LIFT: Life Improvement Trial
Phase 2
160
about 2.2 years
18–70
1 site in MA
What this study is about
This trial is testing whether Pyridostigmine, Low-Dose Naltrexone, or a placebo will help people with Long COVID, ME/CFS, or PASC who have Orthostatic Intolerance. It involves 160 participants and will last for about two years.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Take Low-Dose Naltrexone
- 3.Take Pyridostigmine
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
NERVOUS SYSTEM, pyridostigmine
injection (Injection)
Primary: Physiologic Response - Heart Rate Recovery (HRR)
Secondary: Heart Rate Variability, PROMIS-29-Pain, Resting Heart Rate